Target molecule ADAMTS12 for treating chronic renal insufficiency and renal fibrosis
ADAMTS12 inhibition offers a promising therapeutic strategy to combat fibrosis in chronic kidney disease and heart failure by reducing extracellular matrix production, addressing the limitations of current treatments.
Patent Information
- Application Number
- CN202380083414.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-12-05
- Filing Date
- 2023-12-05
- Publication Date
- 2025-07-15
AI Technical Summary
Currently, there is a lack of effective treatment for chronic renal fibrosis. Existing therapies such as dialysis treatment are accompanied by high mortality and high costs, and the activation mechanism of myofibroblasts is unclear, making fibrosis progress difficult to control.
Identify ADAMTS12 protein as a new molecular target, and binds ADAMTS12 using low-molecular compounds, peptides or biological agents to inhibit its activity, reduce the expression and secretion of extracellular matrix proteins, and reduce fibrosis.
Effectively inhibit the development of kidney and heart fibrosis, reduce the deposition of fibrosis markers, improve organ function, provide new methods for treating chronic kidney disease and heart disease, and reduce mortality and medical expenses.
Smart Images

Figure CN120322676A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the role of ADAMTS12 protein (a disintegrin and metalloproteinase with thrombospondin motifs 12 protein) in the development of chronic kidney disease and heart disease (especially progressive chronic renal insufficiency, renal fibrosis, and the corresponding heart failure and cardiac fibrosis respectively). Specifically, the present invention relates to methods for identifying compounds that bind to and / or inhibit ADAMTS12 protein, and the use of ADAMTS12 protein to screen for and identify compounds that interact with and inhibit ADAMTS12. The present invention also relates to pharmaceutical compositions for treating kidney diseases, especially pharmaceutical compositions comprising an active agent that binds to and / or inhibits ADAMTS12 protein. Background Art
[0002] Fibrosis is defined as the pathological deposition of extracellular connective tissue (extracellular matrix, ECM), which is associated with the displacement of healthy tissue and the loss of organ function. Although the initial deposition of the extracellular matrix is important for maintaining tissue integrity after organ injury, the uncontrolled deposition of the extracellular matrix leads to the displacement of healthy tissue and the loss of organ function. Regardless of the initial injury, fibrosis is almost the common end-stage of all chronic diseases in almost all organs. It is currently believed that in industrialized countries, fibrosis causes up to 45% of total deaths (Henderson et al., 2020). Due to the aging population, the prevalence of fibrosis will continue to increase in the coming decades.
[0003] Globally, the number of patients with chronic renal insufficiency (chronic kidney disease, abbreviated as CKD) is increasing. Current data show that up to 10% of the population in Western countries will develop chronic kidney disease (CKD) in their lifetime (Jha et al., 2013). Due to the increasing average age and the increasing prevalence of hypertension and diabetes, it is expected that the incidence of chronic kidney disease will continue to rise in the future. As renal function declines, morbidity and mortality will increase significantly. At the end stage of chronic kidney disease, dialysis and kidney transplantation are the only treatment options. Due to the long waiting time for donated kidneys, most of these patients receive dialysis treatment. However, dialysis treatment is accompanied by a high mortality rate (the required 5-year survival rate after new dialysis is about 50%, Naylor et al., 2019), numerous complications, and a significant decline in quality of life (dialysis treatment 3 times a week, 4 to 6 hours each time). In addition, the high cost of dialysis is a huge economic burden on the healthcare system (Cm and F, 2017). Therefore, new treatment methods are urgently needed.
[0004] The degree of renal fibrosis is inextricably linked to the loss of renal function and the clinical course of chronic kidney disease. Renal fibrosis is characterized by the high expression, high secretion, and high accumulation of extracellular matrix (ECM) proteins such as type I collagen.
[0005] Myofibroblasts that proliferate after organ injury are the main producers of the extracellular matrix and thus play a key role in the development of fibrosis (Henderson et al, 2020; Kuppe et al., 2021). Although the origin of these myofibroblasts has long been unclear, a perivascular cell population has now been identified, which is characterized by the expression of the transcription factor Gli1, and 50% of the myofibroblasts are derived from this (Kramann et al., 2015a). However, it is still unclear which signals lead to the activation, proliferation, and differentiation of these Gli1 fibroblasts into myofibroblasts.
[0006] The organizational structure of the kidney can be divided into three main parts, all of which can be affected by fibrosis. Specifically, fibrosis in the glomeruli is called glomerulosclerosis, fibrosis in the renal tubulointerstitium is called interstitial fibrosis, and fibrosis in the blood vessels is called arteriosclerosis and perivascular fibrosis (Djudjai and Boor 2019).
[0007] In animal models, inhibiting fibrosis can prevent the progression of chronic renal insufficiency and protect renal function (Kramann et al., 2015a, 2015b). However, there is currently no approved therapy for treating renal fibrosis. The prevalence of chronic renal insufficiency is increasing, so it is crucial to develop drugs for treating fibrosis.
[0008] Therefore, a fundamental object of the present invention is to provide methods and means for identifying active agents, compounds, and compositions, and said active agents, compounds, and compositions for treating chronic kidney disease.
[0009] The present invention discloses the identification of new molecular targets for the treatment of renal fibrosis. After inducing renal fibrosis in mice, fibroblasts expressing Gli1 were identified and isolated, and total RNA (i.e., the expression of all genes expressed by the activated fibroblasts) was analyzed by microarray. On this basis, the present invention unexpectedly identified the protein "a disintegrin and metalloproteinase with thrombospondin motifs 12" (ADAMTS12) as a new molecular target. ADAMTS12 belongs to the ADAMTS metalloproteinase family and can degrade the extracellular matrix protein thrombospondin 5 (Wei et al., 2014). The present invention demonstrates for the first time that the metalloproteinase ADAMTS12 is a key mediator of fibrosis, and knockout (KO) of ADAMTS12 can inhibit the development of fibrosis after kidney and heart injury.
[0010] ADAMTS ("a disintegrin and metalloproteinase with thrombospondin motifs") proteins belong to the metzincin superfamily of proteases, which is named after a conserved methionine residue near the zinc ion-dependent metalloprotease active center (Kelwick et al. 2015). To date, at least 19 different ADAMTS proteins have been identified in the mammalian genome. ADAMTS proteins are secreted extracellular zinc matrix metalloproteases with a unified and ordered modular structure. ADAMTS proteins are initially expressed as inactive proenzymes, and their structure contains a signal peptide, a variable-length propeptide region, a catalytic metalloprotease domain, a disintegrin-like domain, a central thrombospondin type 1-like (TSP) sequence repeat region, a cysteine-rich domain, a spacer region, and a variable number of additional C-terminal TSP repeat regions ( Figure 5 )(Kelwick et al. 2015; Lin et al. 2009).
[0011] The ADAMTS12 gene has a total of 24 exons and encodes an extracellular protein consisting of 1594 amino acids (Mohamedi et al. 2021). Aggrecan, COMP (cartilage oligomeric matrix protein), and α2M (α2-macroglobulin) have been identified as substrates of ADAMTS12. The roles of ADAMTS12 protein in chondrogenesis, cartilage development, and gonadal differentiation, as well as in pediatric stroke, schizophrenia, tumorigenesis, and arthritis, have been described (Lin et al. 2009; Wei et al. 2014; Mohamedi et al. 2021; Witten et al. 2020).
[0012] Accordingly, the present invention discloses ADAMTS12 as a target molecule, thereby providing a new therapeutic approach for the development of therapeutic methods for treating patients with chronic renal insufficiency and renal fibrosis. Summary of the Invention
[0013] The present invention provides methods and means for identifying active agents, compounds, and compositions useful for treating chronic renal insufficiency, particularly for identifying highly effective active agents, compounds, and compositions for treating progressive chronic kidney disease and renal fibrosis.
[0014] In view of the prior art, an object of the present invention is to provide a method for reducing the expression and / or secretion of extracellular matrix (ECM) proteins by specific cells. A further object of the present invention is to provide a method for reducing the expression, differentiation, and secretion of extracellular matrix proteins by (myo)fibroblasts.
[0015] A further object of the present invention is to provide a method for identifying an active agent that can bind to and / or inhibit the ADAMTS12 protein or a fragment thereof.
[0016] A further object of the present invention is to provide a method for identifying an active agent that can bind to ADAMTS12 or a fragment thereof using a nucleic acid encoding the ADAMTS12 protein or a fragment thereof, or the ADAMTS12 protein itself or a fragment thereof.
[0017] A further object of the present invention is to provide, based on the above research results, an active agent useful for treating chronic kidney disease, particularly an active agent useful for treating progressive chronic kidney disease and / or renal fibrosis.
[0018] A further object of the present invention is to provide, based on the above research results, a pharmaceutical composition containing the above active agent, as well as a method for preparing the above pharmaceutical composition.
[0019] The device or method described in the independent claims of the present invention can solve the above and further technical problems. The dependent claims describe preferred embodiments. A numerical range defined by a numerical value should always include the stated limit values.
[0020] The present invention and its generally advantageous embodiments will be explained in more detail below.
[0021] Before describing the present invention in detail, it should be noted that the present invention is not limited to the specific components of the described device nor to the specific steps of the described method, as these methods or devices may vary. It should also be noted that the terms used herein are only for describing specific embodiments and are not intended to be limiting.
[0022] It should be noted that in this specification and the appended claims, singular forms such as "a" or "the" represent a singular and / or plural object unless the context clearly indicates otherwise. If a parameter range is specified, the defined numerical values will be regarded as the boundaries of the disclosed or claimed numerical range.
[0023] It should also be noted that the embodiments disclosed herein should not be construed as individual embodiments that are unrelated to each other. Features discussed in connection with one embodiment should also be regarded as disclosed in connection with other embodiments shown herein. If in a certain situation, a particular feature is not disclosed together with one embodiment but with another embodiment, those skilled in the art should understand that this does not necessarily mean that the feature should not be disclosed together with other embodiments. Those skilled in the art should understand that according to the principles of the present invention, this feature is equally applicable to other embodiments, but for the sake of clarity and to keep the specification within a manageable length, relevant descriptions are not made.
[0024] In addition, the content of the prior art documents cited herein is incorporated herein by reference. This particularly applies to prior art documents that disclose standards or conventional methods. In this case, the main purpose of incorporation by reference is to achieve sufficient disclosure and avoid lengthy repetition.
[0025] According to a first aspect, the present invention relates to a method for reducing the expression and / or secretion of extracellular matrix (ECM) proteins by specific cells, and / or inhibiting fibroblast migration, wherein the method comprises at least one step selected from the group consisting of:
[0026] (i) inhibiting or reducing the expression of the ADAMTS12 gene in cells;
[0027] (ii) inhibiting or reducing the activity of ADAMTS12;
[0028] (iii) inhibiting or reducing the protease activity of ADAMTS12; and / or
[0029] (iv) promoting the degradation of ADAMTS12 protein.
[0030] Inhibiting or reducing the expression of the ADAMTS12 gene includes, for example, ADAMTS12 gene knockdown, gene knockout, conditional gene knockout, gene replacement or mutation, RNA interference, siRNA, and / or antisense RNA.
[0031] Inhibiting or reducing the activity of the ADAMTS12 protein may involve using an active agent that can bind to the ADAMTS12 protein (a disintegrin and metalloproteinase with thrombospondin motifs 12 protein) and / or inhibit or reduce its activity.
[0032] Preferably, the cells are renal cells or cardiac cells, more preferably renal fibroblasts or cardiac fibroblasts, renal myofibroblasts or cardiac myofibroblasts, or renal pericytes or cardiac pericytes; most preferably renal fibroblasts or cardiac fibroblasts.
[0033] The ADAMTS12 protein can be mammalian, non - primate, primate, especially human ADAMTS12 protein or a fragment thereof.
[0034] According to a second aspect, the present invention relates to a method for identifying an active agent that can bind to an ADAMTS12 protein (a disintegrin and metalloproteinase with thrombospondin motifs 12 protein) or a fragment thereof, and / or inhibit or reduce the activity of the ADAMTS12 protein or a fragment thereof.
[0035] The method comprises at least the following steps:
[0036] (i) providing an ADAMTS12 protein or a fragment thereof;
[0037] (ii) adding at least one active agent to be analyzed for binding to the ADAMTS12 protein or a fragment thereof; and
[0038] (iii) identifying at least one active agent that binds to the ADAMTS12 protein or a fragment thereof.
[0039] Preferably, the active agent screened and identified according to the present invention is an ADAMTS12 inhibitor or antagonist, i.e., a reagent that inhibits or reduces the activity of the ADAMTS12 protein or a fragment thereof.
[0040] The active agent according to the present invention can be selected from the group consisting of low - molecular - weight compounds, natural or synthetic peptides or peptide derivatives, and biological agents or bioactive agents.
[0041] In the context of the present invention, the terms "low - molecular - weight compound", "small molecule" ("smol") or "chemical drug" refer to organic compounds with a low molecular weight (< 10,000 daltons, especially < 1,000 daltons), and their size is usually about 1 nm. Many drugs are small molecules. Such small molecules can regulate biological processes. Small molecules may be able to inhibit specific functions of proteins. In the field of pharmacology, the term "small molecule" specifically refers to a molecule that binds to a specific biological macromolecule and acts as an effector by altering the activity or function of the target. For example, acetylsalicylic acid (ASA) is regarded as a low - molecular - weight compound with a molecular weight of 180 daltons and consists of 21 atoms. Such low - molecular - weight compounds generally hardly trigger an immune response and remain relatively stable over time.
[0042] In addition to other chemical backbones, the low-molecular compounds according to the present invention may also contain substituents, groups or molecular groups, such as alkyl, alkenyl, alkynyl, alkoxy, aryl, alkylene, arylene, amino, halogen, carboxylate derivatives, cycloalkyl, carbonyl derivatives, heterocycloalkyl, heteroaryl, heteroarylene, sulfonate, sulfate, phosphonate, phosphate, phosphine or phosphine oxide groups.
[0043] The "biological agent", "biopharmaceutical", "biotherapeutic agent", "biopharmaceutical" or "biologically active agent" according to the present invention is preferably an antibody, its antigen-binding fragment, its antigen-binding derivative, an antibody-like molecule or a protein, an aptamer or a nucleic acid.
[0044] In a preferred embodiment of the method for identifying an active agent that can bind to the ADAMTS12 protein or its fragment, and / or inhibit or reduce the activity of the ADAMTS12 protein or its fragment, the active agent is a member of a "library" of compounds.
[0045] The compound "library" (mixture) may include, for example, low-molecular compounds, natural or synthetic peptides or peptide derivatives, or biologics or biological active agents or biological compounds.
[0046] In the context of the present invention, the term "(combinatorial) compound library" or "compound library" refers to a collection of various chemical compounds, small molecules, natural or synthetic peptides or peptide derivatives, or macromolecules such as proteins or other biological agents. Each collection contains a large number of related chemical, peptide or biological species of molecules, which can be used together in certain screening assays or identification steps.
[0047] The preparation of molecular libraries ("compound libraries") of low-molecular chemical compounds and methods for high-throughput screening of the interactions of these compounds with target molecules have been described in the prior art (e.g., Volochnyuk et al. 2019). These methods also include so-called "focused libraries", i.e., well-annotated and pre-screened libraries of chemical molecules (Wassermann et al. 2014), DNA-encoded libraries of chemical compounds (Martin et al. 2020) and virtual molecular libraries based on chemoinformatics (Saldivar-Gonzalez et al. 2020). For example, Takakusagi et al. (2020) described a method for identifying suitable small-molecule active agents using phage display technology. Valldorf et al. (2022) described many other peptide and antibody display technologies, such as bacterial display, yeast surface display, mammalian surface display and ribosome display.
[0048] Methods for preparing molecular libraries, immobilizing them, and performing high-throughput screening of biomolecules (such as peptides, peptide derivatives, proteins, antibodies, antigen-binding antibody fragments, antigen-binding antibody derivatives, or antibody-like molecules) have also been described in the prior art (for example, for peptide libraries, see Bozovicar and Bratkovic, 2019; Schwaar et al., 2019; for antibody libraries, see Lin and Lerner, 2021).
[0049] In a preferred embodiment of the method for identifying an agent that can bind to the ADAMTS12 protein or a fragment thereof, and / or inhibit or reduce the activity of the ADAMTS12 protein or a fragment thereof, the biological agent is an antibody, its antigen-binding fragment, its antigen-binding derivative, an antibody-like molecule, or a protein, an aptamer, or a nucleic acid.
[0050] In a preferred embodiment of the method for identifying an agent that can bind to the ADAMTS12 protein or a fragment thereof, and / or inhibit or reduce the activity of the ADAMTS12 protein or a fragment thereof, the ADAMTS12 protein is bound to a solid phase or present in solution.
[0051] According to a third aspect, the present invention relates to the use of a nucleic acid encoding the ADAMTS12 protein or a fragment thereof, or the use of the ADAMTS12 protein or a fragment thereof, in a method for identifying an agent that can bind to the ADAMTS12 protein or a fragment thereof, and / or inhibit or reduce the activity of the ADAMTS12 protein or a fragment thereof.
[0052] To express the ADAMTS12 metalloproteinase or a fragment thereof, the nucleic acid encoding the ADAMTS12 metalloproteinase or a fragment thereof is cloned into a suitable expression vector, such as a suitable expression plasmid, as described in (Green and Sambrook, 2012). The recombinant expression plasmid is introduced into cells suitable for expressing ADAMTS12 or a fragment thereof by transfection, the cells are cultured in cell culture using a suitable cell medium, and then the expressed protein is purified from the cells and / or the cell medium.
[0053] As used herein, the term "transfection" refers to any method of deliberately introducing exogenous nucleic acid into eukaryotic cells. Various types of nucleic acids can be used for transfecting eukaryotic cells, particularly deoxyribonucleic acid (DNA), ribonucleic acid (RNA), and small non-coding RNAs, such as small interfering RNA (siRNA), short hairpin RNA (shRNA), and microRNA (miRNA).
[0054] Regarding transfection, it can be divided into stable transfection and transient transfection. In stable transfection, long-term expression of the transgene is achieved by integrating the nucleic acid introduced into the cell into the cell genome; while in transient transfection, the expression of the transgene is only temporary and does not require integration of the nucleic acid into the cell genome.
[0055] The choice of the optimal transfection method depends on various factors, especially the type and origin of the target cells or production cells, and the type of nucleic acid introduced. Transfection methods based on physical, chemical, and viral vectors can be used to introduce exogenous (modified homologous and / or heterologous) nucleic acids encoding the desired transgene into eukaryotic cells. Physical transfection methods include, for example, electroporation, sonoporation, magnetofection, microinjection, and biolistic transfection. Chemical transfection methods include the calcium phosphate method, the use of dendrimers, cationic polymers such as diethylaminoethyl dextran (DEAE-dextran), nanoparticles, non-liposomal nanoparticles, and liposomal transfection. Transfection using viral vectors (so-called "transduction") particularly involves the use of genetically modified retroviruses and lentiviruses, adenoviruses, and adeno-associated viruses (AAV) (Fus-Kujawa et al., 2021).
[0056] According to a fourth aspect, the present invention relates to an active agent obtained by the method of identifying an active agent that can bind to the ADAMTS12 protein or a fragment thereof, and / or inhibit or reduce the activity of the ADAMTS12 protein or a fragment thereof, as described above, or an active agent obtained by any embodiment of the above method.
[0057] Furthermore, the present invention relates to an active agent that can bind to the ADAMTS12 protein or a fragment thereof, and / or inhibit or reduce the activity of the ADAMTS12 protein or a fragment thereof, and / or promote the degradation of the ADAMTS12 protein.
[0058] Furthermore, the present invention relates to an active agent that can inhibit or reduce the expression of the ADAMTS12 gene in renal cells or cardiomyocytes. Preferably, the renal cells are renal fibroblasts, and / or the cardiac cells are cardiac fibroblasts.
[0059] In a preferred embodiment, the present invention relates to an active agent, wherein the active agent is a low molecular weight compound (small molecule), a peptide or a peptide derivative, or a biological agent. Preferably, the biological agent is an antibody or an antigen-binding fragment thereof, an antigen-binding derivative thereof, an antibody-like protein, an aptamer, or a nucleic acid.
[0060] In a preferred embodiment, the active agent specifically binds to the ADAMTS12 protein or a fragment thereof with high or particularly high affinity and / or avidity. In a preferred embodiment, when the active agent binds to ADAMTS12, it can reduce or inhibit the activity of ADAMTS12.
[0061] As used herein, the term "specifically binds" means that the agent has a dissociation constant KD of about 100 micromolar or lower with respect to its binding to an ADAMTS12 protein molecule or an epitope thereof. In one embodiment, the KD is about 100 micromolar or lower, about 50 micromolar or lower, about 30 micromolar or lower, about 20 micromolar or lower, about 10 micromolar or lower, about 5 micromolar or lower, about 1 micromolar or lower, about 900 nanomolar or lower, about 800 nanomolar or lower, about 700 nanomolar or lower, about 600 nanomolar or lower, about 500 nanomolar or lower, about 400 nanomolar or lower, about 300 nanomolar or lower, about 200 nanomolar or lower, about 100 nanomolar or lower, about 90 nanomolar or lower, about 80 nanomolar or lower, about 70 nanomolar or lower, about 60 nanomolar or lower, about 50 nanomolar or lower, about 40 nanomolar or lower, about 30 nanomolar or lower, about 20 nanomolar or lower, or about 10 nanomolar or lower, about 1 nanomolar or lower, about 900 picomolar or lower, about 800 picomolar or lower, about 700 picomolar or lower, about 600 picomolar or lower, about 500 picomolar or lower, about 400 picomolar or lower, about 300 picomolar or lower, about 200 picomolar or lower, about 100 picomolar or lower, about 90 picomolar or lower, about 80 picomolar or lower, about 70 picomolar or lower, about 60 picomolar or lower, about 50 picomolar or lower, about 40 picomolar or lower, about 30 picomolar or lower, about 20 picomolar or lower, or about 10 picomolar or lower, or about 1 picomolar or lower.
[0062] According to a fifth aspect, the present invention relates to an antibody, an antigen-binding fragment thereof, an antigen-binding derivative thereof, or an antibody-like protein that specifically binds to an ADAMTS12 protein.
[0063] In a preferred embodiment, the present invention relates to the above-mentioned antibody, an antigen-binding fragment thereof, an antigen-binding derivative thereof, or an antibody-like protein, wherein the antibody, the antigen-binding fragment thereof, or the derivative or antibody-like protein inhibits the activity of ADAMTS12, i.e., acts as an inhibitor or antagonist of ADAMTS12.
[0064] As used herein, the term "antibody" refers to a protein composed of one or more polypeptide chains encoded by immunoglobulin genes or immunoglobulin gene fragments or cDNA derived therefrom. These immunoglobulin genes include the light chain genes of κ and λ chains, as well as the heavy chain constant region genes of α, δ, ε, γ, and μ, and each of the numerous different variable region genes.
[0065] The basic structural unit of an immunoglobulin (antibody) is usually a tetramer, consisting of two pairs of identical polypeptide chains, namely the light chain (L, with a molecular weight of approximately 25 kDa) and the heavy chain (H, with a molecular weight of approximately 50 to 70 kDa). Each heavy chain consists of a heavy chain variable region (abbreviated as VH or V H ) and a heavy chain constant region (abbreviated as CH or C H ). The heavy chain constant region consists of three domains, namely CH1, CH2, and CH3. Each light chain contains a light chain variable region (abbreviated as VL or V L ) and a light chain constant region (abbreviated as CL or C L ). The VH and VL regions can be further subdivided into hypervariable regions, also known as complementarity-determining regions (CDRs), which are interspersed with more conserved regions called framework regions (FRs). Each VH and VL region consists of three complementarity-determining regions and four framework regions, arranged in the order of FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4 from the amino terminus to the carboxyl terminus. The variable regions of the heavy and light chains form a binding domain that interacts with the antigen.
[0066] The complementarity-determining regions (CDRs) are the most important for the binding of an antibody or its antigen-binding portion. The framework regions (FRs) can be replaced by other sequences as long as the three-dimensional structure required for antigen binding is retained.
[0067] The "antigen-binding portion" of a (monoclonal) antibody refers to one or more fragments of the antibody that retain the ability to specifically bind to the antigen in its native form. Examples of the antigen-binding portion of an antibody include the Fab fragment, which is a monovalent fragment consisting of the light chain variable region (VL), the heavy chain variable region (VH), the light chain constant region (CL), and the first domain of the heavy chain constant region (CH1); the F(ab')2 fragment, which is a bivalent fragment consisting of two Fab fragments linked by a disulfide bond in the hinge region; the Fd fragment, which consists of the heavy chain variable region (VH) and the first (CH1) domain of the heavy chain constant region; the Fv fragment, which consists of the light chain variable region (VL) and the heavy chain variable region (VH) domains of a single arm of the antibody; and the dAb fragment, which consists of the heavy chain variable region (VH) domain and a separated complementarity-determining region (CDR).
[0068] The antibody, antibody fragment, or antibody derivative thereof according to the present invention can be a monoclonal antibody. The antibody can be of the IgA, IgD, IgE, IgG, or IgM isotype.
[0069] As used herein, the term "monoclonal antibody (mAb)" refers to an antibody composition having a homogeneous population of antibodies (i.e., a homogeneous population consisting of intact immunoglobulins or fragments or derivatives thereof). Particularly preferred are such antibodies selected from the group consisting of IgG, IgD, IgE, IgA, and / or IgM or fragments or derivatives thereof.
[0070] As used herein, the term "fragment" refers to fragments of such antibodies that retain their target binding ability, for example, complementarity determining regions (CDRs), hypervariable regions, variable domains (Fv), IgG heavy chains (consisting of a heavy chain variable region (VH), the first domain of the heavy chain constant region (CH1), a hinge region, the second domain of the heavy chain constant region (CH2), and the third domain of the heavy chain constant region (CH3)), IgG light chains (consisting of a light chain variable region (VL) and a light chain constant region (CL)), and / or Fab and / or F(ab)2 fragments.
[0071] As used herein, the term "derivative" refers to a protein construct that is structurally different from the common antibody concept but still has a certain structural relationship thereto, such as single-chain variable fragments (scFv), Fab, and / or F(ab)2, as well as bispecific, trispecific, or higher specificity antibody constructs. All of these terms will be explained below.
[0072] Other antibody derivatives known to those skilled in the art include diabodies, camelid antibodies, domain antibodies, bivalent homodimers consisting of two chains of single-chain variable fragments (scFv), IgA (two IgG structures linked by a J chain and a secretory component), Hai antibodies, antibodies consisting of a New World primate framework plus non-New World primate complementarity determining regions (CDRs), dimerization constructs containing the third domain of the heavy chain constant region (CH3), a light chain variable region (VL), and a heavy chain variable region (VH), other framework protein forms containing complementarity determining regions (CDRs), and antibody conjugates.
[0073] As used herein, the term "antibody-like protein" refers to a protein that has been modified (e.g., by mutating immunoglobulin loops) to specifically bind to a target molecule. Typically, such an antibody-like protein contains at least one variable peptide loop that is linked to a protein framework at both ends. This dual structural constraint raises the binding affinity of the antibody-like protein to a level comparable to that of an antibody. The length of the variable peptide loop generally consists of 10 to 20 amino acids. The framework protein can be any protein with good solubility. Preferably, the framework protein is a small globular protein. Antibody-like proteins include, but are not limited to, affibodies, anticalins, designed ankyrins, and affilin bodies. Antibody-like proteins can be obtained from large libraries of mutants, e.g., by screening from large phage display libraries, and can be isolated by methods similar to those for conventional antibodies. Antibody-like binding proteins can also be obtained by combinatorial mutagenesis of surface-exposed groups in globular proteins. Antibody-like proteins have been described, for example, in Binz et al. (2005) and Hosse et al. (2006).
[0074] As used herein, the term "Fab" refers to an IgG fragment that contains an antigen-binding region, where the fragment consists of the constant and variable domains of the antibody heavy and light chains, respectively.
[0075] As used herein, the term "F(ab)2" refers to an IgG fragment consisting of two Fab fragments linked by a disulfide bond.
[0076] As used herein, the term "scFv" refers to a single-chain variable fragment, which is a fusion of the variable regions of the immunoglobulin heavy and light chains linked by a short linker that typically contains serine (S) and / or glycine (G) groups. Although the constant regions are removed and a linker peptide is introduced, this chimeric molecule still retains the specificity of the original immunoglobulin.
[0077] Modified antibody forms include, for example, bispecific or trispecific antibody constructs, antibody-based fusion proteins, immunoconjugates, and the like.
[0078] IgG, single-chain variable fragments (scFv), Fab, and / or F(ab)2 are antibody forms well known to those skilled in the art. Relevant detailed explanations and techniques can be found in relevant textbooks.
[0079] According to a preferred embodiment of the present invention, the antibody, its antigen-binding fragment, or its antigen-binding derivative is a murine antibody, a chimeric antibody, a humanized antibody, or a human antibody, or an antigen-binding fragment or antigen-binding derivative thereof.
[0080] Murine monoclonal antibodies (mAbs) can cause adverse immune side effects because they contain proteins from other species that can trigger an immune response. To overcome this problem, antibody humanization and maturation methods have been developed to produce antibody molecules with minimal immunogenicity when used in humans, while ideally retaining the specificity and affinity of the non-human parental antibody. In these methods, for example, the framework regions of murine monoclonal antibodies are replaced with the corresponding human framework regions (so-called complementarity-determining region (CDR) grafting). WO200907861 discloses a method for preparing a humanized form of a murine antibody by linking the complementarity-determining region (CDR) regions of a non-human antibody to a human constant region using recombinant DNA technology. U.S. Patent US6548640 describes complementarity-determining region grafting technology, and U.S. Patent US5859205 describes a method for preparing humanized antibodies.
[0081] As used herein, the term "humanized antibody" refers to an antibody, fragment, or derivative thereof in which at least a portion of the constant region and / or framework region, and optionally a portion of the complementarity-determining region (CDR) regions, are derived from or adapted to human immunoglobulin sequences.
[0082] According to a sixth aspect, the present invention relates to the above-mentioned active agent, or the above-mentioned antibody, antigen-binding fragment or antigen-binding derivative thereof, or the above-mentioned antibody-like protein, for the treatment of chronic kidney disease and / or heart disease.
[0083] In this case, the chronic kidney disease is preferably progressive chronic renal insufficiency and / or renal fibrosis. The heart disease is preferably heart failure, myocardial infarction and / or cardiac fibrosis.
[0084] Furthermore, the present invention relates to a pharmaceutical composition comprising the above-mentioned active agent, or the above-mentioned antibody, antigen-binding fragment or antigen-binding derivative thereof, or the above-mentioned antibody-like protein, and one or more pharmaceutically acceptable excipients, for the treatment of chronic kidney disease and / or heart disease, preferably, wherein the chronic kidney disease is progressive chronic kidney disease, renal insufficiency and / or renal fibrosis, and preferably, wherein the heart disease is heart failure and / or cardiac fibrosis.
[0085] In a preferred embodiment of the present invention, the pharmaceutically acceptable excipients are selected from the group consisting of pharmaceutically acceptable buffers, surfactants, diluents, carriers, excipients, fillers, binders, lubricants, slip additives, disinfectants, adsorbents, and / or preservatives.
[0086] The pharmaceutical composition can be administered in the form of powder, tablets, pills, capsules or microbeads. For aqueous pharmaceutical formulations, they can be ready for administration, while lyophilized formulations need to be converted into a liquid form before administration, for example, by adding water for injection, which may or may not contain preservatives, including but not limited to benzyl alcohol, antioxidants (such as vitamin A, vitamin E, vitamin C, vitamin D, benzyl alcohol), antioxidants (such as vitamin A, vitamin E, vitamin C, retinyl palmitate and selenium), amino acids (such as cysteine and methionine), citric acid and sodium citrate, synthetic preservatives (such as methylparaben and propylparaben).
[0087] The pharmaceutical formulation can further comprise one or more stabilizers, which can be, for example, amino acids, sugar alcohols, disaccharides and / or polysaccharides. The pharmaceutical formulation can further comprise one or more surfactants, one or more isotonizing agents and / or one or more metal ion chelators and / or one or more preservatives.
[0088] The pharmaceutical formulations described herein are at least suitable for oral, parenteral, intravenous, intramuscular or subcutaneous administration. Alternatively, the active agent or antibody according to the invention can be made into a sustained-release formulation such that the active agent can be released continuously over a period of time.
[0089] The present invention also provides a primary package, such as a pre-filled syringe or pen injector, vial or infusion bag, which contains the pharmaceutical formulation according to this aspect of the present invention.
[0090] The formulation contained in the pre-filled syringe or pen injector can be in lyophilized form (which must be dissolved, for example, with water for injection before administration) or in aqueous form. The syringe or pen injector is usually for single use and has a capacity between 0.1 mL and 20 mL. However, the syringe or pen injector can also be a reusable syringe or a multi-dose pen injector.
[0091] Furthermore, the present invention relates to the use of an active agent that binds to the ADAMTS12 protein in a method for treating chronic kidney disease and / or heart disease, wherein the chronic kidney disease is preferably progressive chronic kidney disease, renal insufficiency and / or renal fibrosis, and / or the heart disease is preferably heart failure and / or cardiac fibrosis. Preferably, when the active agent binds to ADAMTS12, it can inhibit the activity of ADAMTS12.
[0092] In addition, the present invention relates to the use of an active agent that binds to ADAMTS12 protein in the preparation of a medicament for treating chronic kidney disease and / or heart disease, wherein the chronic kidney disease is preferably progressive chronic renal insufficiency and / or renal fibrosis, and the heart disease is preferably heart failure and / or cardiac fibrosis. Preferably, when the active agent binds to ADAMTS12, the activity of ADAMTS12 can be inhibited.
[0093] In addition, the present invention relates to a method for treating or preventing chronic kidney disease and / or heart disease, which method comprises administering to a human or animal subject a therapeutically effective dose or amount of an active agent that binds to and / or inhibits ADAMTS12 protein.
[0094] As used herein, the term "effective dose" or "effective amount" refers to the dose or amount of the active agent that is necessary, in terms of dose and administration time, to achieve the desired therapeutic effect in a patient. The effective amount may vary depending on various factors such as the disease state, the age, sex and / or weight of the patient, the pharmaceutical formulation, the subtype of the disease being treated, etc., but the skilled person in the art can routinely determine such effective amount.
[0095] According to a seventh aspect, the present invention relates to a method for preparing an active agent according to the method of identifying an active agent that binds to ADAMTS12 protein or a fragment thereof, and / or inhibits or reduces the activity of ADAMTS12 protein or a fragment thereof as described above, which further comprises the step of purifying the active agent.
[0096] The present invention also relates to a method for preparing a pharmaceutical composition, which method comprises:
[0097] (i) the method of identifying an active agent that binds to ADAMTS12 protein or a fragment thereof, and / or inhibits or reduces the activity of ADAMTS12 protein or a fragment thereof as described above, and further
[0098] (ii) mixing the identified active agent with a pharmaceutically acceptable carrier.
[0099] According to an eighth aspect, the present invention relates to a composition comprising a combination of the following components:
[0100] (i) an active agent that binds to ADAMTS12 protein or a fragment thereof, and / or inhibits or reduces the activity of ADAMTS12 protein or a fragment thereof as described above, or an antibody, an antigen-binding fragment or antigen-binding derivative thereof, or an antibody-like protein as described above, or a pharmaceutical composition comprising the active agent as described above, or the antibody, an antigen-binding fragment or antigen-binding derivative thereof, or an antibody-like protein as described above and one or more pharmaceutically acceptable excipients, and
[0101] (ii) One or more other therapeutically active compounds.
[0102] According to the ninth aspect, the present invention relates to a therapeutic kit, comprising:
[0103] (i) The pharmaceutical composition as described above;
[0104] (ii) A device for administering the composition; and
[0105] (iii) Optionally, instructions for use.
[0106] Sequence Listing:
[0107] Table 1: Amino acid sequence of human ADAMTS12 (UniProt-ID: P58397-1)
[0108]
[0109] Description of the Drawings
[0110] Figure 1: Microarray analysis of Gli1 fibroblasts after unilateral ureteral obstruction (UUO).
[0111] (A) Experimental setup.
[0112] (B) Hallmark gene set enrichment analysis (GSEA) based on differentially expressed genes in Gli1 fibroblasts after unilateral ureteral obstruction.
[0113] (C) Display of the "top 25" upregulated genes in Gli1 fibroblasts after unilateral ureteral obstruction, sorted according to the T value.
[0114] (D) Representative in situ hybridization (ISH) images of Pdgfrb and Adamts12 transcripts in mouse kidneys at different time points after ischemia-reperfusion (IRI).
[0115] (E) Quantitative analysis of Adamts12 in situ hybridization expression.
[0116] (F) Quantitative analysis of Pdgfrb in situ hybridization expression.
[0117] (G) Quantitative analysis of Adamts12 in situ hybridization expression in Pdgfrb-positive cells.
[0118] **p < 0.01, ***p < 0.001.
[0119] Figure 2: Adamts12 gene deletion prevents fibrosis.
[0120] (A - G) Adamts12 gene knockout (Adamts12- / -) or wild-type (WT) mice were subjected to unilateral ureteral obstruction (UUO) surgery or sham surgery (Sham). Ten days after the surgery, the mice were sacrificed and the kidneys were removed.
[0121] (A) Reverse transcription quantitative polymerase chain reaction (RT-qPCR) of Adamts12.
[0122] (B) Reverse transcription quantitative polymerase chain reaction of type I collagen (Collagen 1, Col 1a1).
[0123] (C) Reverse transcription quantitative polymerase chain reaction of fibronectin (Fn1).
[0124] (D) Immunofluorescence staining (IF) of platelet-derived growth factor receptor β (PDGFRb).
[0125] (E) Quantitative analysis of PDGFRb expression detected by immunofluorescence.
[0126] (F) Immunohistochemistry (IHC) staining of type I collagen (Col 1).
[0127] (G) Quantitative analysis of type I collagen expression detected by immunohistochemistry.
[0128] (H - I) Adamts12 gene knockout (Adamts12- / -) or wild-type (WT) mice were subjected to myocardial infarction (MI) surgery or sham surgery (Sham).
[0129] (H) Echocardiography was used to measure the left ventricular ejection fraction (LV-EF) in wild-type and Adamts12 gene knockout mice after myocardial infarction or sham surgery.
[0130] (I) The degree of fibrosis was measured by continuous section Sirius red staining in wild-type and Adamts12 gene knockout mice after myocardial infarction or sham surgery.
[0131] *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.001.
[0132] Figure 3: Knockout of the ADAMTS12 gene using CRISPR-Cas9 in human renal PDGFRb-positive fibroblasts.
[0133] After stimulation with a control or transforming growth factor β (TGFβ), reverse transcription quantitative polymerase chain reaction (RT-qPCR) of ADAMTS12 or type I collagen α1 chain (COL1A1) was performed on control (non-targeting guide RNA, non-targeting gRNA) groups and human renal PDGFRb fibroblasts with CRISPR knockout of the ADAMTS12 gene (ADAMTS12-KO).
[0134] (C) After stimulation with a control or transforming growth factor β (TGFβ), migration assays were performed on control (non-targeting guide RNA, non-targeting gRNA) groups and human renal PDGFRb fibroblasts with CRISPR knockout of the ADAMTS12 gene (ADAMTS12-KO).
[0135] (D) Protein immunoblotting was performed on human renal PDGFRb fibroblasts, including: a group with CRISPR knockout (KO) of the ADAMTS12 gene and transfection with an empty expression plasmid pMIG (no protein-coding nucleotide sequence inserted), a group with CRISPR knockout of the ADAMTS12 gene and overexpression of HA-tagged ADAMTS12 (WT) using the pMIG expression plasmid, and a group overexpressing the catalytically inactive HA-tagged ADAMTS12 protein (Mut) using the pMIG expression plasmid, to detect the HA epitope, tubulin, and enhanced green fluorescent protein (eGFP).
[0136] (E) Migration assays were performed on human renal PDGFRb fibroblasts, including: a group with CRISPR knockout of the ADAMTS12 gene (ADAMTS12-KO) and transfection with an empty expression plasmid pMIG (no protein-coding nucleotide sequence inserted), a group with CRISPR knockout of the ADAMTS12 gene and overexpression of the HA-tagged ADAMTS12 protein (ADAMTS12-KO with WT), and a group overexpressing the catalytically inactive HA-tagged ADAMTS12 protein (Mut).
[0137] Figure 4: Expression of ADAMTS12 in the human kidney.
[0138] (A) Expression of ADAMTS12 in CD10-negative, stroma-rich renal single cells (after removal of proximal tubular cells) isolated from 15 human kidneys by fluorescence-activated cell sorting (FACS).
[0139] (B) Expression of ADAMTS12 in PDGFRb-positive single cells isolated from 8 human kidneys by fluorescence-activated cell sorting (FACS).
[0140] (C) Representative images of in situ hybridization of PDGFRB, COL1A1, and ADAMTS12 in 43 human kidneys.
[0141] (D) Quantitative analysis of in situ hybridization. Shows the proportion of cells that are positive for both ADAMTS12 and PDGFRB among ADAMTS12-positive cells.
[0142] (E) Correlation of in situ hybridization expression of ADAMTS12 and PDGFRB in human kidney tissue.
[0143] (F) Correlation of in situ hybridization expression of ADAMTS12 and COL1A1 in human kidney tissue.
[0144] Figure 5 : Domain structure and composition of ADAMTS12 protein. The N-terminus of ADAMTS12 consists of a signal peptide, a prodomain, and a metalloprotease domain. The C-terminus of ADAMTS12 includes a disintegrin-like domain, the first thrombospondin type 1 repeat (TSP1), a cysteine-rich domain, and an additional 7 TSP1 repeats separated by two spacer domains. The second spacer domain is a mucin-like domain (from Wei et al. 2014). Detailed implementation manners
[0145] The present invention is described in more detail by the following examples and the accompanying drawings. It should be noted that these examples and drawings are only for description and do not limit the present invention in any way.
[0146] The present invention is not limited to the disclosed implementation manners. Those skilled in the art can understand and implement other variants of the disclosed implementation manners by studying the drawings, the present disclosure, and the appended claims. In the claims, the word "comprising" does not exclude other elements or steps, and the indefinite article "a" or "an" does not exclude a plurality. Just because certain measures are mentioned in different dependent claims does not mean that the combination of these measures cannot bring beneficial effects. Any reference signs in the claims should not be construed as limiting the scope of application.
[0147] All amino acid sequences disclosed herein are shown from the N-terminus to the C-terminus; all nucleic acid sequences disclosed herein are shown in the 5'→3' direction.
[0148] Example 1: Materials and methods
[0149] Mice:
[0150] Gli1CreER t2(Jackson Laboratory strain #007913) and Rosa26tdTomato (Jackson Laboratory strain #007909) were purchased from the Jackson Laboratory (Bar Harbor, Maine, USA). Offspring were genotyped by polymerase chain reaction (PCR) according to the Jackson Laboratory's protocol. ADAMTS12 gene knockout (KO) mice were generated by C. Lopez-Otin (ElHour et al., 2010). All mice were genotyped by PCR. These mice were housed under specific pathogen-free conditions at RWTH Aachen University.
[0151] Handling of mice:
[0152] Unilateral ureteral obstruction (UUO) surgery: After making an incision in the lateral abdomen, the left ureter was ligated at the level of the lower pole of the kidney with two 7.0 silk ligatures (Ethicon). Ischemia-reperfusion surgery (IRI): After making an incision in the lateral abdomen, the renal artery was clamped with an aneurysm clip for 26 minutes. For the sham operation, only a lateral abdominal incision was made. Mice were sacrificed 10 days after unilateral ureteral surgery or 28 days after ischemia-reperfusion surgery. The animal experimental protocol was approved by the North Rhine-Westphalia State Office for Nature, Environment and Consumer Protection in Germany. All animal experiments were conducted in accordance with their guidelines. For the inducible lineage tracing experiment, Gli1CreER; tdTomato mice (8 weeks old) were gavaged with tamoxifen three times (10 mg orally each time). Administration of tamoxifen caused the Cre recombinase to translocate into the nuclei of cells expressing Gli1, which cleaved the loxP DNA sequences. The recombination process removed the stop codon, enabling the downstream fluorophore tdTomato to be expressed in Gli1-expressing cells. This allowed Gli1-positive cells to be genetically labeled after tamoxifen administration. Twenty-one days after tamoxifen administration, unilateral ureteral obstruction (UUO) surgery or sham surgery was performed, and the mice were sacrificed 10 days after the surgery. The sacrificed mice were perfused through the left ventricle with 20 ml of 0.9% sodium chloride solution to remove residual blood from the vascular system. Myocardial infarction and sham myocardial infarction were performed as previously described (Curaj et al., 2015). Briefly, mice were anesthetized with isoflurane (2%-2.5%), and after intubation, they were ventilated with oxygen using a mouse ventilator (Harvard Apparatus, Holliston, MA, USA). For analgesia, in addition to local analgesia by subcutaneous and intercostal injection of bupivacaine (2.5 μg per gram of body weight), analgin was also injected subcutaneously (200 μg per gram of body weight). After left thoracotomy, sham myocardial infarction surgery (without any intervention) or myocardial infarction surgery was performed by ligating the left anterior descending artery (LAD) with a silk suture (0-7). Then the ribs, muscle layer, and skin incision were sutured with prolene sutures (0-6). Postoperative analgesia was provided for three days with analgin (1.25 mg / ml in a 1% sucrose solution) added to the drinking water.
[0153] Single-cell isolation and fluorescence-activated cell sorting (FACS):
[0154] The kidney was removed surgically, cut into small slices, and then placed in a 15-ml tube (Falcon) containing ice-cold phosphate-buffered saline with 1% fetal bovine serum (PBS with 1% FBS). The kidney tissue was then transferred to a C tube (Miltenyi Biotec), and processed on a gentle-MACS (Miltenyi Biotec) using the spleen program 4. The tissue was digested in RPMI medium (Gibco) containing 25 μg / ml neutral protease TL (Roche) and 50 μg / ml deoxyribonuclease (Sigma) at 37 °C with shaking (300 rpm) for 30 min. After incubation, the samples were processed again on a gentle-MACS (Miltenyi Biotec) using the same program. The resulting cell suspension was passed through a 70-μm cell strainer (Falcon), washed with 45 ml cold PBS, and then centrifuged at 500 g for 5 min at 4 °C. Cells were counted using a hemocytometer with trypan blue staining. Using this method, the overall cell viability exceeded 80%. The isolated cells were resuspended in ice-cold PBS containing 1% fetal bovine serum at a final concentration of 1×10 7 cells / ml. Live single cells were FACS sorted using a FACS Aria II device (Becton Dickinson, Basel, Switzerland) by setting gates for Gli1-tdTomato-positive and DAPI-negative cells. On average, it took 5 to 6 h from biopsy sample collection to preparation of the single-cell suspension.
[0155] Affymetrix microarray data analysis:
[0156] The microarray gene expression of the mouse genome “Mouse4302.db” was quantified using the R language software package “affy” and normalized using the robust multi-chip average method (RMA). The RunLimma function in the R language software package Limma (version 3.44.1) was used to detect gene expression differences between the unilateral ureteral obstruction (UUO) surgery group and the sham surgery (Sham) group. When microarray samples were mapped to the same gene multiple times, duplicate genes were removed. Differentially expressed genes were ranked according to the T value. For pathway analysis, the R language software package “fgsea” was used to perform analysis based on all differentially expressed genes in combination with hallmark signaling pathways.
[0157] RNA in situ hybridization:
[0158] In situ hybridization (ISH) was performed using formalin-fixed, paraffin-embedded tissue samples and the RNAScope Multiplex Assay Kit V2 (a product of RNAScope, #323100). The operation was carried out according to the manufacturer's protocol with some minor modifications. Antigen retrieval was performed for 30 minutes. After antigen retrieval, 3 to 5 drops of pretreatment 1 solution were incubated at room temperature for 10 minutes. The washing steps were carried out three times, each for 5 minutes. The probes used for RNAScope detection were as follows: mouse Pdgfrb probe #411381-C3, mouse Adamts12 probe #400531, human PDGFRβ probe #548991-C1, human COL1A1 probe #401891-C2, human Adamts12 probe #509701-C3.
[0159] Confocal imaging:
[0160] Images were acquired using a Nikon A1R confocal microscope with 40x and 60x objectives (products of Nikon Corporation). The raw data was processed using Nikon software or ImageJ software.
[0161] Image quantification - In situ hybridization (ISH) image analysis:
[0162] The renal cortex region was randomly selected by the system, and at least 7 representative tubulointerstitial regions were selected for each image. The images were segmented into RGB channels using ImageJ software, the background was subtracted (rolling ball radius: 10.0 pixels), and the fluorescent dots (transcripts) were counted. For cell classification, 3 representative Z-stack images (Z-stack images refer to multiple images acquired using a confocal microscope, which are taken at a certain distance between the first and last focal planes in the same region) were obtained from each sample. The Z-stack images were overlaid to form a so-called Z-projection image and segmented into RGB channels using ImageJ software. Cells were segmented and classified using a trained algorithm through the ilastik object classification workflow (Berg et al., 2019).
[0163] Quantitative reverse transcription polymerase chain reaction (qRT-PCR):
[0164] For RNA extraction from cultured cells, the cells were first washed with PBS and then lysed with RNA-Easy lysis buffer. For RNA extraction from kidney tissues, the tissues were transferred to an Eppendorf tube containing 400 μL of RNA-Easy lysis buffer and digested using a homogenizer (2 x 2 min, 20 Hz). Then, RNA extraction was performed using the RNeasy Mini kit (Qiagen) according to the manufacturer's instructions. 200 ng of RNA was reverse-transcribed into cDNA using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems). qRT-PCR was performed using the iTaq Universal SYBR Green Supermix (Bio-Rad) and the Bio-Rad CFX96 Real-Time System with a C1000 Touch Thermal Cycler. The cycling conditions were: 95°C for 3 min, followed by 40 cycles of 95°C for 15 s and 60°C for 1 min, and finally one cycle of 95°C for 10 s. GAPDH was used as the housekeeping gene. Data were analyzed using the 2-ΔΔCT method. The primers used are listed in Table 2.
[0165] Table 2: Primer sequences for reverse transcription polymerase chain reaction (qRT-PCR) (human)
[0166]
[0167]
[0168] Immunofluorescence staining and quantitative analysis:
[0169] Kidney sections embedded in 2-μm-thick paraffin and fixed with formalin were mounted on slides in 10% bovine serum, followed by incubation with the primary antibody for 1 hour, washing three times with PBS for 5 minutes each, and then incubation with the secondary antibody for 30 minutes. After staining with DAPI (4′,6-diamidino-2-phenylindole, product of Roche, diluted 1:10,000), mounting was performed using ImmuMount (9990402, product of Epredia). Four representative images of the renal cortex were taken from each sample using a 40× objective of a Nikon A1R confocal microscope. For quantitative analysis, the images were segmented into RGB channels, and the fluorescence areas were quantified using ImageJ software. The antibodies used were as follows: anti-mouse PDGFRβ antibody (ab32570, diluted 1:100, product of Abcam), AF488-labeled donkey anti-rabbit antibody (711-545-152, diluted 1:200, product of Jackson ImmunoResearch), AF647-labeled donkey anti-rat antibody (712-605-153, diluted 1:200, product of Jackson ImmunoResearch).
[0170] Immunohistochemical staining and quantitative analysis:
[0171] After dewaxing the 2-μm-thick paraffin sections, the sections were heated three times in antigen retrieval solution (H-33000, product of Vector Laboratories) for 5 minutes each for antigen retrieval. Then, they were incubated with 3% hydrogen peroxide for 3 minutes, followed by incubation with avidin / biotin (VEC-SP-2001, product of Vector Laboratories) for 10 minutes, and then incubation with the primary antibody for 1 hour. After washing three times with PBS, the secondary antibody was incubated. Detection was performed using a DAB substrate kit (SK-4100, product of Vector Laboratories). Finally, the sections were counterstained with hematoxylin, dehydrated, and covered with cover slips. Seven representative images of the renal cortex were taken from each section using a 40× objective of a bright-field microscope (BZ-9000, product of Keyence, immunohistochemistry). The antibodies used were as follows: anti-mouse type I collagen (Col1) antibody (1310-01, diluted 1:100, product of Southern Biotech), biotinylated horse anti-goat antibody (BA-9500, diluted 1:300, product of Vector Laboratories).
[0172] Mouse echocardiography:
[0173] At 2 days before myocardial infarction, 4 weeks and 8 weeks after myocardial infarction, the cardiac function of the left ventricle of mice was measured using a small animal ultrasound scanner (Vevo 3100 and MX550D sensors, product of Fujifilm Visualsonics, Inc., Toronto, Ontario, Canada). The short axis and long axis of the heart, left ventricular end-diastolic and end-systolic volumes, and heart rate were measured using a 40 MHz sensor (MX550D) in B-mode (two-dimensional real-time) and M-mode. During the examination, the mice were anesthetized with 1%-2% isoflurane. All measurement data were analyzed using VevoLab software.
[0174] Sirius red staining and quantitative analysis:
[0175] Sirius red staining was performed using a Morphisto-Sirius red staining kit (13425, product of Morphisto). The whole slide was scanned using an Aperio slide scanner (product of Leica Biosystems), and the fibrotic area stained red by the Sirius red kit was quantitatively analyzed using the Aperio eSlide Manager program.
[0176] Handling of human tissues:
[0177] Human kidney tissues were obtained from normal regions according to the previously described method (Kuppe et al., 2021). The tissues were frozen with dry ice or placed in pre-cooled University of Wisconsin solution (#BTLBUW, product of Bridge to Life Ltd., Columbia, USA) and transported to the laboratory on ice. To isolate human kidney single cells, a method combining enzymatic digestion and mechanical disruption was adopted, and the specific operation was the same as the method for isolating mouse single cells described above.
[0178] Fluorescence-activated cell sorting (FACS) of human tissues:
[0179] The isolated cells were stained and sorted according to the previously described method (Kuppe et al., 2021). Briefly, the isolated cells were resuspended on ice in PBS containing 1% fetal bovine serum at a final concentration of 1×10 7cells / ml. Cells were pre-incubated with Fc blocker (TruStain FcX human type, TruStain FcX mouse clone 91, products of Biolegend), and then incubated with anti-human CD10 antibody (clone HI10a, products of Biolegend) diluted with 2% fetal bovine serum / PBS for 30 minutes on ice in the dark. To stain with anti-human PDGFRβ antibody, goat anti-mouse DyLight405 (poly24091, products of Biolegend) was used as the secondary antibody. When acquiring data, all compensation operations were performed using single-color staining, negative staining, and fluorescence minus one (FMO) controls. Single cells were enriched by FACS sorting and gating on DAPI-negative cells, and fibroblasts were further enriched by PDGFRβ staining. Cell sorting was performed in semi-purity mode using a Sony SH800 cell sorter (products of Sony Biotechnology Inc.; 100 μm nozzle sorting chip, products of Sony) with a target sorting efficiency of greater than 80%.
[0180] 10X Genomics 3' single-cell RNA sequencing (sc-RNA-Seq, versions V2 and V3) single-cell detection:
[0181] Single-cell detection was performed according to the method described previously (Kuppe et al., 2021). Briefly, a single-cell suspension of primary human kidney cells was loaded onto a Chromium single-cell chip kit, and the library was processed using the Chromium single-cell 3' library kit V2 and i7 multiplex kit (product numbers PN-120236, PN-120237, PN-120262, products of 10x Genomics) according to the manufacturer's protocol. The library quality was detected using a D1000 ScreenTape on a 2200 TapeStation system (products of Agilent Technologies). Sequencing was performed on an Illumina Novaseq platform using S1 and S2 flow cells (products of Illumina).
[0182] Human kidney tissue microarray:
[0183] Paraffin-embedded kidney microarrays were prepared according to the previously described method (Kuppe et al., 2021). Briefly, formalin-fixed, paraffin-embedded kidney samples were selected from the Aachen biomaterial library according to the results of periodic acid-Schiff (PAS) staining performed previously. Random areas were selected from each sample, and a 2-mm tissue core was taken from each kidney sample using a TMArrayerTM (Pathology Devices, Beecher Instruments, Westminster, USA). Each tissue core was placed in a receiving block with a 2-mm grid covering an area of approximately 2.5 cm 2 and 5-μm thick sections were cut and processed using standard histological techniques.
[0184] Human PDGFRβ + Cell line establishment:
[0185] An immortalized human kidney PDGFRβ-positive cell line was used in in vitro experiments. The method for establishing this cell line has been described in a previous study (Kuppe et al., 2021).
[0186] TGFβ treatment experiment:
[0187] TGFβ (100-21-10UG, Peprotech) at a concentration of 10 ng / ml in PBS was added to PDGFRβ at 75% confluence after culturing in starvation medium (medium containing 0.5% fetal bovine serum) for 24 hours.
[0188] sgRNA:CRISPR-Cas9 vector construction, virus preparation and transduction
[0189] The ADAMTS12-specific guide RNA (forward sequence: 5′-CACCGAACATCATAGATCACTCCGG-3′; reverse sequence: 5′-AAACCCGGAGTGATCTATGATGTTC-3′) was digested with BsmBI restriction enzyme and cloned into the pL-CRISPR.EFS.GFP plasmid (Addgene No. 57818). Lentiviral transfer plasmid, packaging plasmid psPAX2 (Addgene No. 12260), and VSVG packaging plasmid pMD2.G (Addgene No. 12259) were transiently co-transfected into HEK293T cells using TransIT-LT (Mirus) to produce lentiviral particles. The viral supernatant was collected 48 - 72 hours after transfection, centrifuged to clarify, supplemented with 10% fetal bovine serum and Polybrene (Sigma-Aldrich, final concentration 8 μg / ml), and filtered through a 0.45 μm filter (Millipore; product number SLHP033RS). Cell transduction was performed by incubating PDGFRβ cells with the viral supernatant for 48 hours. Cells expressing eGFP were sorted individually into 96-well plates. To determine the mutation status of both alleles in the cultured clones, the PCR products of the ADAMTS12 clones were subcloned into the pCR TM 4Blunt-TOPO vector (Thermo Scientific, product number K287520). At least 6 colonies of each CRISPR clone were cultured and sequenced (clone C2: 30 colonies were sequenced). Meanwhile, qPCR was performed to confirm the deletion of ADAMTS12 gene expression.
[0190] Retroviral overexpression of ADAMTS12:
[0191] The construction of the ADAMTS12 vector and the establishment of a cell line stably overexpressing ADAMTS12 are as follows: The cDNA of human ADAMTS12 was synthesized by combining two gblock gene fragments (IDT) ([1] Xho-N-terminal-EcoRI and [2] EcoRI-C-terminal-1xHA tag-EcoRI) and fused with the continuous coding sequence (CDS) with a C-terminal 1xHA tag in the destination vector. Due to the high complexity score of the C-terminal fragment, its codons were optimized. First, the two gBlock gene fragments were blunt-ended and ligated into the pSC-B-amp / kan plasmid using the StrataClone BluntPCR cloning kit (product number 240207) to construct vectors (a) pSC_Adamts12_AA1-160 and (b) pSC_Adamts12_AA611-1595-HA. The N-terminal fragment was transferred from the pSC vector to the pMIG backbone (Addgene plasmid number 9044) using restriction cloning with XhoI and EcoRI restriction enzymes to construct plasmid pMIG-Adamts12_AA1-160. Subsequently, the N-terminal was transferred from the pSC vector to the target plasmid by EcoRI restriction cloning ("in-frame" cloning). The H465Q-E466A mutation was introduced using the Q5 site-directed mutagenesis kit (NEB; product number E0554) and primers Mut-H465Q-466A-F: 5′-CACAATTGCCcaagcgCTAGGACACAG-3′ and Mut-H465-E466A-R: 5′-AAAGCCAGAGGGAGTCCC-3′. The CDS (wild-type and mutant ADAMTS12) was controlled by sequencing. Transient transfection was performed using TransIT-LT (Mirus) in combination with the packaging plasmid pUMVC (Addgene plasmid number 8449) and the pseudotyped plasmid pMD2.G (Addgene plasmid number 12259; http: / / n2t.net / addgene:12259; RRID:Addgene_12259) to prepare retroviral particles. The viral supernatant was collected 48 - 72 hours after transfection, centrifuged to clarify, supplemented with 10% fetal bovine serum and Polybrene (Sigma-Aldrich, final concentration 8 μg / ml), and filtered through a 0.45 μm filter (Millipore; product number SLHP033RS). The PDGFβ cells were incubated with the viral supernatant for 48 hours for cell transduction. Cells expressing eGFP were purified by fluorescence-activated cell sorting.
[0192] Western Blot:
[0193] To extract proteins, cells were lysed with RIPA buffer containing protease inhibitor cocktail (Roche). Protein concentration in the lysates was measured using Pierce BCA Protein Assay Kit (Product No. 23225, Thermo Scientific). Subsequently, protein lysates adjusted to the same concentration were denatured at 95 °C for 5 minutes in SDS sample loading buffer (BioRad) and then loaded onto a 10% SDS-PAGE gel. After gel electrophoresis, the samples were transferred to a PVDF membrane and incubated with the primary antibody (anti-HA epitope tag antibody (BioLegend, Product No. 901533) diluted 1:2000) diluted in a solution containing 5% Blotto (Thermo Fisher) for 2 hours. After washing, the membrane was incubated with the secondary antibody (horseradish peroxidase (HRP)-labeled anti-mouse antibody, Vector Laboratories) for 1 hour, and finally developed using Pierce TM ECL Western Blotting Substrate A and B. Anti-tubulin monoclonal antibody and anti-GFP goat antibody (Rockland, Product No. 600-101-215, diluted 1:2000), and the corresponding HRP-labeled anti-mouse and anti-goat secondary antibodies (both from Vector Laboratories) were used as loading controls, respectively.
[0194] Migration analysis:
[0195] Cells were seeded in Matrigel-coated 96-well plates (flat bottom, transparent, Product No. 89626, ibidi). After incubation with starvation medium (containing 0.5% fetal bovine serum) for 24 hours, cells at 50% confluence were stimulated with 10 ng / ml TGFβ in CO₂-free medium (Product No. 18045054, Gibco). After 24 hours of stimulation, the spontaneous fluorescence of the cells was recorded every 10 minutes for 18 - 24 hours using a Nikon A1R confocal microscope in a 37 °C incubator. Cells at each time point were segmented using the pixel classification workflow of ilastik and then exported as so-called "prediction maps". Subsequently, the prediction maps at different time points for each region were aligned and integrated, and cell coordinates and average velocity were calculated using the ImageJ plugins StackReg and TrackMate. The velocity was weighted according to the length of individual tracks. The cell motility was calculated using the ggplot2 package in R and graphically presented. These graphs show representative results from a total of three independent experiments.
[0196] Single-cell RNA analysis:
[0197] The collection and analysis of single-cell RNA data, including transcript alignment, normalization, scaling, dimensionality reduction, and cell annotation, were performed as previously described (Kuppe et al., 2021). Gene expression analysis of ADAMTS12 was performed using the Seurat package in R.
[0198] Quantitative and statistical analysis outside of single-cell sequencing and microarray data
[0199] Unless otherwise stated in the figure legends, data are presented as mean ± standard deviation. Unpaired t-tests were used for comparisons between two groups. Multiple groups were compared using two-way analysis of variance (ANOVA) combined with Tukey's multiple comparison test. Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software, Inc., San Diego, CA). A p-value less than 0.05 was considered statistically significant.
[0200] Example 2: Overexpression of the ADAMTS12 gene in activated fibroblasts after kidney injury
[0201] To identify new signaling pathways that may contribute to Gli1 fibroblast activation, in Gli1-CreER(t2) and R26tdTomato mice, fibroblasts expressing the transcription factor Gli1 (Gli1 fibroblasts) were genetically labeled with the fluorophore tdTomato by repeated administration of tamoxifen. Twenty-five days after induction with tamoxifen, unilateral ureteral obstruction (UUO) surgery was performed to induce renal fibrosis, or sham surgery was performed as a control group. Ten days after surgery, the mice were sacrificed, and Gli1 fibroblasts were isolated from the kidneys of the UUO group or the control group using fluorescence-activated cell sorting (FACS) technology, and RNA transcriptomes were measured using Affymetrix microarray analysis ( Figure 1A ). Principal component analysis (PCA) verified that activated Gli1 fibroblasts after UUO were significantly different from non-activated Gli1 fibroblasts in the kidneys of the control group (sham surgery group). Subsequently, gene set enrichment analysis (GSEA) was performed based on hallmark pathways ( Figure 1B ). GSEA results showed that the normalized enrichment scores (NES) of pro-inflammatory pathways (inflammatory immune response, IL6-STAT3, TNFA via NFKB signaling pathway), myofibroblast-related pathways (epithelial-mesenchymal transition, TGF-β pathway), and proliferation-related pathways (G2M checkpoint, mitotic spindle, E2F targets) were significantly increased. This indicates that Gli1 fibroblasts proliferate and differentiate into myofibroblasts after UUO. In gene expression analysis, the upregulation of pro-inflammatory genes and extracellular matrix genes was most obvious ( Figure 1C)。Among the most significantly upregulated genes (top 6 ranked by T value) in activated Gli1 fibroblasts is the ADAMTS12 gene (a disintegrin and metalloproteinase with thrombospondin motifs 12).
[0202] ADAMTS12 belongs to the ADAMTS metalloproteinase family; previously, the role of ADAMTS12 in the pathogenesis of fibrosis was unclear.
[0203] To validate these new findings, after inducing renal fibrosis by ischemia-reperfusion injury (IRI), RNA in situ hybridization was performed on ADAMTS12 and the fibroblast marker PDGFRβ ( Figure 1D ). In situ hybridization staining showed that the ADAMTS12 gene was minimally expressed under homeostatic conditions and was sharply upregulated only in PDGFRβ-positive fibroblasts after kidney injury ( Figure 1E -G).
[0204] Based on these findings, the inventors surprisingly found that ADAMTS12 was one of the most significantly upregulated genes in Gli1 fibroblasts after unilateral ureteral obstruction (UUO).
[0205] Example 3: Reducing renal and cardiac fibrosis in vivo by knocking out ADAMTS12
[0206] Based on the microarray data obtained, unilateral ureteral obstruction (UUO) surgery was performed in wild-type and ADAMTS12 gene knockout (KO) mice (Adamts12 - / - ). Quantitative real-time polymerase chain reaction (RT-qPCR) was used to detect the gene expression of ADAMTS12 and the extracellular matrix (ECM) proteins type I collagen (Col1a1) and fibronectin (Fn1) ( Figure 2A -C). Knockout of the ADAMTS12 gene resulted in the absence of ADAMTS12 expression at the RNA level ( Figure 2A ). In addition, in ADAMTS12 gene knockout (KO) mice after UUO surgery, the gene expression of type I collagen and fibronectin was significantly reduced. The results of polymerase chain reaction (RT-qPCR) were verified by immunofluorescence staining of the fibroblast marker PDGFRβ and immunohistochemical staining of the extracellular matrix protein type I collagen ( Figure 2D 、 2F ). Quantitative analysis of PDGFRβ showed that after UUO surgery, the proliferation of PDGFRβ fibroblasts was significantly reduced in ADAMTS12 gene knockout mice ( Figure 2E ). In addition, the deposition of type I collagen was also significantly reduced in ADAMTS12 gene knockout (ADAMTS12-KO) mice.Figure 2G )。
[0207] To analyze whether these results are applicable to the pathogenesis of chronic heart failure and cardiac fibrosis, myocardial infarction (MI) was induced in wild-type and ADAMTS12 gene knockout mice by ligating the left anterior descending coronary artery. The results confirmed again that ADAMTS12 gene deletion improved left ventricular ejection fraction (LV-EF) after myocardial infarction and reduced fibrosis ( Figure 2H 、I).
[0208] In summary, surprisingly, knockout of ADAMTS12 reduced renal and cardiac fibrosis after organ injury, and in the case of myocardial infarction, even reduced functional loss. From these results, it can be concluded that ADAMTS12 plays a key role in the activation of Gli1 fibroblasts.
[0209] Example 4: Reduction of myofibroblast differentiation and migration of human fibroblasts in vitro by CRISPR-CAS9-mediated ADAMTS12 knockout
[0210] Subsequently, based on the in vivo experimental results (Example 3, Figure 2), the function of the metalloproteinase ADAMTS12 was studied in vitro to determine whether ADAMTS12 is essential for fibroblast proliferation and differentiation into myofibroblasts. The CRISPR-Cas9 technique was used to induce ADAMTS12 gene knockout (KO) in immortalized human renal PDGFRβ-positive fibroblasts ( Figure 3A ). First, the ability of ADAMTS12 gene knockout and wild-type (WT) fibroblasts to differentiate into myofibroblasts was studied by stimulation with transforming growth factor β (TGFβ). In this experiment, it was confirmed that knockout of ADAMTS12 reduced the expression of type I collagen (COL1A1), which is a marker of myofibroblast differentiation ( Figure 3A 、 3B ). An important step in fibroblast activation is the migration of fibroblasts from the perivascular niche to the stroma and their proliferation. Therefore, in a second experiment, the migration of wild-type and ADAMTS12 gene knockout fibroblasts was analyzed using confocal microscopy. The results showed that ADAMTS12 deletion significantly reduced fibroblast migration after TGFβ stimulation ( Figure 3C ).
[0211] To analyze whether the observed effects of ADAMTS12 are mediated by its metalloprotease domain, as previously described, in immortalized human kidney PDGFRβ-positive fibroblasts with ADAMTS12 knocked out by a CRISPR-Cas9 vector, the ADAMTS12-pMIG expression vector was transduced by retrovirus to express catalytically active (wild type, WT) or catalytically inactive (mutant, Mut.) ADAMTS12( Figure 3D ). Overexpression of catalytically active ADAMTS12 (WT) led to increased fibroblast migration after activation, while overexpression of catalytically inactive ADAMTS12 (Mut.) did not affect migration( Figure 3E ). These results confirmed that ADAMTS12 induces fibroblast migration through its metalloprotease domain.
[0212] Therefore, knocking out ADAMTS12 by CRISPR-Cas9 reduces myofibroblast differentiation and migration of human fibroblasts in vitro. Catalytically active ADAMTS12 can induce the migration of human fibroblasts in vitro.
[0213] Example 5: Specific fibroblast and myofibroblast populations express ADAMTS in the human kidney
[0214] Next, the expression of ADAMTS12 in the human kidney was analyzed. The expression of ADAMTS12 was analyzed in a dataset of 15 human kidneys (Kuppe et al., 2021), in which CD10-negative cells were sequenced separately (to enrich interstitial cells). The results showed that ADAMTS12 was specifically expressed by fibroblasts and myofibroblasts, and to a lesser extent by pericytes( Figure 4A ). These results were confirmed in a second dataset, in which single-cell sequencing was performed on PDGFRβ-positive cells from 8 human kidneys( Figure 4B ). Single-cell data indicated that a subset of fibroblasts and myofibroblasts expressed ADAMTS12. To verify these results, additional in situ hybridization of ADAMTS12, PDGFRβ, and type I collagen (COL1A1) was performed in 43 human kidneys( Figure 4C ). This confirmed that ADAMTS12 was mainly produced by PDGFRβ-positive fibroblasts( Figure 4D ), and the expression of ADAMTS12 was significantly correlated with the expression of the fibroblast marker PDGFRβ and the extracellular matrix protein type I collagen( Figure 4E 、 4F ).
[0215] Example 6: Screening for active agents that bind to and / or inhibit the activity of metalloprotease ADAMTS12
[0216] The screening experiments help to identify and validate low-molecular-weight therapeutic compounds, peptides, and / or biologics that can bind to the ADAMTS12 protein and / or inhibit its activity.
[0217] According to the methods described in the existing literature (Kunig et al. 2018), a library of DNA-encoded substances is constructed and screened. In addition, phage display technology (Takakusagi et al. 2020), cell surface display or ribosome display technology (Galán et al. 2016), and / or combinatorial peptide libraries (Bozovicar and Bratkovic 2019) will also be used. For this purpose, recombinant ADAMTS12 protein or its fragments carrying "tags" (such as His-tag or FLAG-tag) for labeling, identification, or purification are expressed in bacterial expression systems such as Escherichia coli, insect cells, or mammalian cells.
[0218] The purified ADAMTS12 protein is incubated with the substance library and then separated by immunoprecipitation. For example, compounds that bind to the ADAMTS12 protein are identified by Sanger sequencing of DNA barcodes. Subsequently, the effects of the identified active agents and compounds on ADAMTS12 function, its protease activity, fibroblast migration, the expression and secretion of matrix proteins (such as type I collagen and fibronectin), and the development of renal fibrosis and / or cardiac fibrosis are tested. For this purpose, in vivo models of experimental mice with renal fibrosis and cardiac fibrosis are used.
[0219] To identify and validate low-molecular-weight therapeutic compounds, peptides, and / or biologics that act on the protease activity or expression of ADAMTS12, a fluorescence reporter system based on human cells in vitro is established. For example, using the expression of eGFP-ADAMTS12 fusion protein or a luciferase-based reporter system, the substance library is screened in 384- to 1536-well assays to identify compounds that can reduce eGFP fluorescence or luciferase levels, and these are used as readouts. The expression of these human ADAMTS12 fusion reporter constructs in these cells can be achieved by transfection and screening with a resistance gene cassette or by viral transduction. Human cell lines such as 293T cells and established human renal fibroblast cell lines can be used for these assays. During this screening, cytotoxicity assays are carried out to exclude compounds that affect the reporter fluorescence or activity due to non-specific toxicity or induction of apoptosis.
[0220] In summary, based on the experimental data presented, ADAMTS12 was identified for the first time as a potential molecular target for the treatment of fibrosis using microarray analysis of Gli1 fibroblasts. In in vivo experiments, it was demonstrated for the first time in mouse models of unilateral ureteral obstruction (UUO) and myocardial infarction (MI) that knockout of ADAMTS12 significantly reduced fibroblast migration and fibrosis. In in vitro experiments, knockout of ADAMTS12 using CRISPR-Cas9 decreased the migration of human renal PDGFRβ-positive fibroblasts, while overexpression of catalytically active (but not catalytically inactive) ADAMTS12 enhanced cell migration. This confirmed that the observed effects of ADAMTS12 were mediated by its metalloprotease domain.
[0221] In the human kidney, ADAMTS12 has been shown to be specifically produced by fibroblasts, myofibroblasts, and to a lesser extent, pericytes. In addition, the expression of ADAMTS12 is correlated with the expression of the fibroblast marker PDGFRβ and the fibrosis marker type I collagen.
[0222] The metalloprotease ADAMTS12 has been less studied previously, and there are no reports on its involvement in the pathogenesis of renal or cardiac fibrosis. Some studies have shown that ADAMTS12 is a negative regulator of angiogenesis (EI Hour et al., 2010), while other research groups have reported that ADAMTS12 can regulate the immune response and that knockout of ADAMTS12 leads to an extended pro-inflammatory immune response (Moncada-Pazos et al., 2018; Paulissen et al., 2012).
[0223] The metalloprotease ADAMTS12 is an attractive molecular target for the treatment of fibrosis. Under homeostatic conditions, ADAMTS12 is barely expressed or not expressed at all. After induction of renal fibrosis, ADAMTS12 is specifically upregulated in fibroblasts, pericytes, and myofibroblasts. The cell-specific expression of ADAMTS12 and its low or absent expression under homeostatic conditions suggest that inhibition of ADAMTS12 may have fewer side effects. In addition, from a biochemical perspective, inhibition of the metalloprotease ADAMTS12 provides a clear entry point for drug development.
[0224] References:
[0225] Binz, H.K., Amstutz, P., and Plückthun, A. (2005). Engineering novel binding proteins from nonimmunoglobulin domains. Nature Biotechnology Vol.23 Nr.10, 1257 - 1268.
[0226] Bozovicar, K., and Bratkovic, K. (2019). Evolving a Peptide: Library Platforms and Diversification Strategies. Int. J. Mol. Sci. 21, 215.
[0227] Berg, S. et al. (2019). ilastik: interactive machine learning for (bio)image analysis. Nature Methods 16, 1226–1232.
[0228] Cal, S., et al. (2001). Identification, characterization, and intracellular processing of ADAM - TS12, a novel human disintegrin with a complex structural organization involving multiple thrombospondin - 1 repeats. J. Biol. Chem. 276, 17932 - 17940.
[0229] Cm, V., and F, S. (2017). A comparison between the costs of dialysis treatments in Marche Region, Italy: Macerata and Tolentino hospitals. Ann. Ist. Super. Sanita 53, 344 - 349.
[0230] Curaj, A., et al. (2015). Minimal invasive surgical procedure of inducing myocardial infarction in mice. J. Vis. Exp. JoVE e52197.
[0231] Djudjai, S. & Boor, P. (2019). Cellular and molecular mechanisms of kidney fibrosis. Mol. Aspects Med. 65, 16 - 36.
[0232] El Hour, M., Moncada - Pazos, A., Blacher, S., Masset, A., Cal, S., Berndt, S., Detilleux, J., Host, L., Obaya, A. J., Maillard, C., et al. (2010). Higher sensitivity of Adamts12 - deficient mice to tumor growth and angiogenesis. Oncogene 29, 3025 - 3032.
[0233] Fus - Kujawa A. et al. (2021). An overview of methods and tools for transfection of eukaryotic cells in vitro. Front. Bioeng. Biotechnol. Vol. 9:701031.
[0234] Galán et al. (2016). Library - based display technologies: where do we stand? Molecular Biosystems. DOI:10.1039 / c6mb00219f.
[0235] Green M. R. and Sambrook J. (2012). Molecular Cloning. A Laboratory Manual. Fourth Edition. Cold Spring Harbor Laboratory Press.
[0236] Henderson, N.C., Rieder, F., and Wynn, T.A. (2020). Fibrosis: from mechanisms to medicines. Nature 587, 555 - 566.
[0237] Hosse, R.J., Rothe, A., and Power, B.E. (2006). A new generation of protein display scaffolds for molecular recognition. Protein Science 15:14–27.
[0238] Jha, V., Garcia - Garcia, G., Iseki, K., Li, Z., Naicker, S., Plattner, B., Saran, R., Wang, A.Y.-M., and Yang, C.-W. (2013). Chronic kidney disease: global dimension and perspectives. Lancet Lond. Engl. 382, 260 - 272.
[0239] Kelwick, R., et al. (2015). The ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family. Genome Biology 16:113.
[0240] Kramann, R., DiRocco, D.P., and Humphreys, B.D. (2013). Understanding the origin, activation and regulation of matrix - producing myofibroblasts for treatment of fibrotic disease. J. Pathol. 231, 273 - 289.
[0241] Kramann, R., Schneider, R. K., DiRocco, D. P., Machado, F., Fleig, S., Bondzie, P. A., Henderson, J. M., Ebert, B. L., and Humphreys, B. D. (2015a). Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 16, 51-66.
[0242] Kramann, R., Fleig, S. V., Schneider, R. K., Fabian, S. L., DiRocco, D. P., Maarouf, O., Wongboonsin, J., Ikeda, Y., Heckl, D., Chang, S. L., et al. (2015b). Pharmacological GLl2 inhibition prevents myofibroblast cell-cycle progression and reduces kidney fibrosis. J. Clin. Invest. 125, 2935-2951.
[0243] Kunig, V. et al. (2018). DNA-encoded libraries–an efficient small molecule discovery technology for the biomedical sciences. Biol. Chem. 399(7), 691–710.
[0244] Kuppe, C. et al. (2021). Decoding myofibroblast origins in human kidney fibrosis. Nature 589, 281-286.
[0245] Lin C.-W. and Lerner R.A. (2021). Antibody libraries as tools to discover functional antibodies and receptor pleiotropism. Int. J. Mol. Sci. Vol. 22 No. 4 123. https: / / doi.org / 10.3390 / ijms22084123.
[0246] Lin, E.A., and Liu, C. (2009). The emerging roles of ADAMTS-7 and ADAMTS-12 matrix metalloproteinases. Open Access Rheumatology Research and Reviews. Vol. 1, 121–131.
[0247] Martin A. et al. (2020). Navigating the DNA-encoded libraries chemical space. Communications Chemistry Vol. 3 No. 1 27. https: / / doi.org / 10.1038 / s42004-020-00374-1.
[0248] Mohamedi, Y., et al. (2021). ADAMTS-12: Functions and Challenges for a Complex Metalloprotease. Frontiers in Molecular Biosciences. Vol. 8, Article 686763.
[0249] Moncada-Pazos, A., Obaya, A.J., Lamazares, M., Heljasvaara, R., M.F., Colado, E., A., Cal, S., and López-Otin, C. (2018). ADAMTS-12 metalloprotease is necessary for normal inflammatory response. J. Biol. Chem. 293, 11648.
[0250] Naylor, K.L., Kim, S.J., McArthur, E., Garg, A.X., McCallum, M.K., and KnolI, G.A. (2019). Mortality in Incident Maintenance Dialysis Patients Versus Incident Solid Organ Cancer Patients: A Population-Based Cohort. Am. J. Kidney Dis. Off. J. Natl. Kidney Found. 73, 765 - 776.
[0251] Paulissen, G., El Hour, M., Rocks, N., Gueders, M.M., Bureau, F., Foidart, J.-M., López-Otin, C., Noel, A., and Cataldo, D.D. (2012). Control of allergen-induced inflammation and hyperresponsiveness by the metalloproteinase ADAMTS-12. J. Immunol. Baltim. Md 1950 189, 4135 - 4143.
[0252] Saldivar-Gonzalez F.I. et al. (2020). Chemoinformatics-based enumeration of chemical libraries: a tutorial. Journal of Cheminformatics Vol.12 No.64. https: / / doi.org / 10.1186 / s13321-020-00466-z.
[0253] Schwaar T. et al. (2019). Efficient screening of combinatorial peptide libraries by spatially ordered beads immobilized on conventional glass slides. High-Throughput Vol.8 No.11. doi:10.3390 / ht8020011.
[0254] Takakusagi et al.(2020)Phage display technology for target determination of small-molecule therapeutics:an update.Expert Opinion on Drug Discovery.Vol.15,No.10,1199–1211.
[0255] Valldorf B.et al.,(2022).Antibody display technologies:selecting the cream of the crop.Biol.Chem.Vol.403 No.5–6,p.455–477.
[0256] Volochnyuk D.M.et al.(2019).Evolution of commercially available compounds for HTS.Drug Discovery Today Vol.24 No.2,p.390-402.
[0257] Wassermann A.M.et al.(2014).Composition and applications of focus libraries to pheno-typic assays.Frontiers in Pharmacology Vol.5 No.164.doi:10.3389 / fphar.2014.00164.
[0258] Wei,J.,Richbourgh,B.,Jia,T.,and Liu,C.(2014).ADAMTS-12:a multifaced metalloproteinase in arthritis and inflammation.Mediators Inflamm.2014,649718.
[0259] Witten,A.,et al.(2020).ADAMTS12,a new candidate gene for pediatric stroke.PLoS ONE 15(8):e0237928.
Claims
1. A method of reducing the expression and / or secretion of extracellular matrix (ECM) proteins by specific cells, and / or inhibiting fibroblast migration, wherein, The method includes at least one step selected from the group consisting of: (i) inhibiting or reducing the expression of the ADAMTS12 gene in a cell; (ii) inhibiting or reducing the activity of ADAMTS12; (iii) inhibiting or reducing the activity of the ADAMTS12 protease; and / or (iv) promoting the degradation of the ADAMTS12 protein.
2. The method according to claim 1, wherein, Inhibiting or reducing the expression of the ADAMTS12 gene includes ADAMTS12 gene knockdown, gene knockout, conditional gene knockout, gene modification, RNA interference, siRNA, and / or antisense RNA.
3. The method according to claim 1, wherein Inhibiting or reducing the activity of ADAMTS12 includes using an active agent that binds to the ADAMTS12 protein (a disintegrin and metalloproteinase with thrombospondin motifs 12 protein).
4. The method according to any one of claims 1 to 3, wherein, The cell is a renal cell or a cardiac cell, preferably a renal fibroblast or a cardiac fibroblast, a renal myofibroblast or a cardiac myofibroblast, or a renal pericytes or a cardiac pericytes; most preferably, it is a renal fibroblast or a cardiac fibroblast.
5. A method for identifying an active agent that can bind to the ADAMTS12 protein (a disintegrin and metalloproteinase with thrombospondin motifs 12 protein) or a fragment thereof, and / or inhibit or reduce the activity of the ADAMTS12 protein or a fragment thereof.
6. The method according to claim 5, comprising at least the following steps: (i) providing the ADAMTS12 protein or a fragment thereof; (ii) adding at least one active agent to be analyzed for binding to the ADAMTS12 protein or a fragment thereof; (iii) identifying at least one active agent that has bound to the ADAMTS12 protein or a fragment thereof.
7. The method according to any one of claims 5 and 6, wherein The active agent is an ADAMTS12 inhibitor.
8. The method according to any one of claims 5 to 7, wherein, The active agent is a member of a compound library.
9. The method according to any one of claims 5 to 8, wherein, The active agent is selected from the group consisting of low molecular weight compounds, peptides, and biological agents.
10. The method according to claim 9, wherein, The biological agent is an antibody, an antigen-binding fragment thereof, an antigen-binding derivative thereof, an antibody-like molecule, or an aptamer.
11. The method according to any one of claims 5 to 10, wherein, The ADAMTS12 protein is bound to a solid phase or present in solution.
12. A nucleic acid encoding the ADAMTS12 protein or a fragment thereof, or the use of the ADAMTS12 protein or a fragment thereof in the method according to any one of claims 5 to 11 for identifying an active agent that can bind to the ADAMTS12 protein or a fragment thereof.
13. An active agent obtained by the method according to any one of claims 5 to 11.
14. An active agent that can inhibit or reduce the expression of the ADAMTS12 gene in renal cells or cardiac cells. Preferably, The renal cell is a renal fibroblast, and / or the cardiac cell is a cardiac fibroblast.
15. An active agent that can bind to the ADAMTS12 protein (a disintegrin and metalloproteinase with thrombospondin motifs 12 protein) or a fragment thereof, and / or inhibit or reduce the activity of the ADAMTS12 protein or a fragment thereof, and / or promote the degradation of the ADAMTS12 protein.
16. The active agent according to any one of claims 13 to 15, wherein, The active agent is a low molecular weight compound (small molecule), a peptide, or a biological agent, preferably, wherein the biological agent is an antibody or a fragment thereof, a derivative thereof, an antibody-like protein, or an aptamer.
17. An antibody, an antigen-binding fragment thereof, an antigen-binding derivative thereof, or an antibody-like protein that can specifically bind to ADAMTS12 protein.
18. The antibody, antigen-binding fragment thereof, antigen-binding derivative thereof or antibody-like protein according to claim 17, wherein, The antibody, antigen-binding fragment or derivative thereof, or antibody-like protein can inhibit the activity of ADAMTS12.
19. The active agent according to any one of claims 13 to 16, or the antibody, antigen-binding fragment thereof, antigen-binding derivative thereof, or antibody-like protein according to any one of claims 17 and 18, for treating chronic kidney disease and / or heart disease.
20. The active agent, antibody, antigen-binding fragment thereof, antigen-binding derivative thereof or antibody-like protein according to claim 19, wherein, The chronic kidney disease is progressive chronic renal insufficiency and / or renal fibrosis, and / or the heart disease is heart failure and / or myocardial fibrosis.
21. Use of an active agent capable of binding to ADAMTS12 protein in a method for treating chronic kidney disease and / or heart disease, wherein, The chronic kidney disease is preferably progressive chronic kidney disease, renal insufficiency and / or renal fibrosis, wherein the heart disease is preferably cardiac insufficiency and / or myocardial fibrosis.
22. Use of an active agent capable of binding to ADAMTS12 protein in the preparation of a medicament for treating chronic kidney disease and / or heart disease, wherein, The chronic kidney disease is preferably progressive chronic renal insufficiency and / or renal fibrosis, wherein the heart disease is preferably heart failure and / or myocardial fibrosis.
23. Use of the active agent according to any one of claims 21 and 22, wherein When the active agent binds to ADAMTS12, it can inhibit the activity of ADAMTS12.
24. A method for treating or preventing chronic kidney disease and / or heart disease, wherein, The method includes administering a therapeutically effective dose of an active agent that can bind to and / or inhibit ADAMTS12 protein to a human or animal subject.
25. The method for preparing an active agent according to any one of claims 5 to 11, further including purifying the active agent.
26. A pharmaceutical composition comprising an active agent according to any one of claims 13 to 16, or an antibody, an antigen-binding fragment thereof, an antigen-binding derivative thereof or an antibody-like protein according to any one of claims 17 and 18, and one or more pharmaceutically acceptable excipients, for the treatment of chronic kidney disease and / or heart disease, preferably, wherein, The chronic kidney disease is progressive chronic kidney disease, renal insufficiency and / or renal fibrosis, preferably, wherein the heart disease is heart failure and / or myocardial fibrosis.
27. The pharmaceutical composition according to claim 26, wherein, The excipients are selected from the group consisting of pharmaceutically acceptable buffers, surfactants, diluents, carriers, excipients, fillers, binders, lubricants, glidants, disinfectants, adsorbents, and / or preservatives.
28. A method for preparing a pharmaceutical composition, including: (i) The method according to any one of claims 5 to 11; and (ii) Mixing the identified active agent with a pharmaceutically acceptable carrier.
29. A composition, which comprises a combination of the following components: (i) An active agent that can bind to ADAMTS12 protein according to any one of claims 13 to 16, an antibody or an antigen-binding fragment thereof, an antigen-binding derivative thereof, or an antibody-like protein according to any one of claims 17 and 18, or the pharmaceutical composition according to any one of claims 26 and 27; and (ii) One or more other therapeutically active compounds.
30. A treatment kit, including: (i) The pharmaceutical composition according to any one of claims 26, 27 or 29; (ii) A device for administering the composition; and (iii) Optional instructions for use.
Citation Information
Patent Citations
Humanised antibodies
US5859205A
Altered antibodies
US6548640B1
Implantable RF defibrillator
WO2009007861A1
